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A) Study title 
Are primary care consultations for insomnia associated with dementia in later life? 
B) Lay summary 
Insomnia has been defined as a difficulty initiating or maintaining sleep, leading to sleep that is either  
insufficient or unrefreshing. It is well-established that insomnia is more common in people with dementia, 
but it is not clear if insomnia predates dementia in these individuals. This latter question is an important 
one: if it can be shown that people with insomnia are more likely to develop dementia in later life, this may 
improve our ability to predict an individual’s dementia risk, and possibly to help manage that risk. Several 
recent studies have found a link between insomnia and later dementia, but typically give little information 
about the time between the onset of insomnia and the onset of dementia, raising the possibility that the 
insomnia is an early symptom of dementia, rather than a risk factor or potential cause of the disease. 
Furthermore, in some studies the link between insomnia and dementia becomes weaker when factors such 
as depression and sleeping tablet use are taken into account.  
The proposed study uses primary care records to learn whether people with dementia are more likely to 
have consulted with their general practitioner (GP) about insomnia 5-10 years earlier, compared to those 
who do not have dementia. 
C) Technical summary 
We propose a 1:1 matched case-control study, using 8414 anonymised GP records already acquired for our 
main study (Protocol 15_111R). The study aims to explore the association between insomnia and later 
dementia. 
Insomnia consultations will be identified using relevant Read codes. Our measure of insomnia will be the 
the number of months in which the patient consulted the GP about insomnia, during the period 5-10 years 
before the index date (defined for cases as the first coded diagnosis of dementia). This 5-10 year exposure 
window will help address the problem of ‘reverse causality’, whereby we might record insomnia episodes 
which are merely an early symptom of dementia, rather than a risk factor for later disease.  
We will use conditional logistical regression to estimate the odds ratio (OR) of developing dementia in 
those exposed compared to those not exposed, and to control for covariates including benzodiazepine and 
z-drug use, mental and physical health comorbidities, and GP visit frequency. 
 
D) Objectives, Specific Aims and Rationale 
Our objective is to understand the association between dementia and previous insomnia, as measured by 
the number of months in which the patient consults the GP about insomnia.  
We aim to answer the following research questions: 
RQ1. In the period 5-10 years prior to the index date (i.e. first diagnosis of dementia), do people with 
dementia consult their GP about insomnia more frequently than controls?  
RQ2. Does any association between insomnia and dementia remain significant after controlling for 
variables such as benzodiazepine and z-drug use, physical health comorbidities and history of mental 
illness? 
RQ3. If a sensitivity analysis is performed, looking at different exposure windows (6-11 and 7-12 years 
prior to the index date), does any association between insomnia and dementia remain? 
E) Study background 
The prevalence of insomnia among patients in primary care ranges from 10 to 50% (1). A strong association 
between duration of insomnia and later dementia would be of clinical relevance, with the possibility of 
using insomnia as a prognostic marker for dementia, or even a treatable risk factor. 
But while it is well-established that insomnia is common in dementia (2), it is less clear whether the 
insomnia predates the development of dementia. Here is a summary of some important papers: 
● A recent meta-analysis of prospective cohort studies reported significantly higher risk (RR=1.53) of 
all-cause dementia in the elderly with previous insomnia (3). However, little information on the 
latency between the onset of insomnia and the onset of dementia is available. 
● A longitudinal study (4) found that reduced sleep was associated with a 75% increase in risk of 
dementia, but results were no longer significant after adjusting for depressive symptoms, 
respiratory problems and pain. 
● A large prospective cohort study using the Caerphilly Cohort (5) found no significantly increased risk 
of either Alzheimer’s disease or vascular dementia in those reporting insomnia 10 years previously 
(although those reporting daytime sleepiness and sleep apnoea had an increased risk of vascular 
dementia).  
● A study of midlife sleep (mean age = 52) and cognitive impairment and dementia 18 to 26 years 
later in >2,300 Finnish twins found no association with Alzheimer’s for poor sleep or hypnotic use 
(6).  
In a recent retrospective cohort study from Taiwan, those with insomnia prescribed hypnotics were more 
likely to develop dementia during three years of follow-up than those with insomnia  not prescribed 
hypnotics (7). This highlights the confounding role that hypnotics may play when analysing the relationship 
between sleep and dementia. 
F) Study type 
The study is hypothesis-testing. The null hypothesis is that there is no association between dementia and 
previous insomnia.  
G) Study design 
The study has a matched case-control design.  
H) Feasibility counts 
We will be using data already obtained for the main study (Protocol 15_111R), which comprised  50,000 
cases and 50,000 controls. However, due to new exclusion criteria (most notably the requirement that 
patients have ten years of data preceding their index date), the total number of cases and controls eligible 
for the new study is 8414. 
I) Sample size considerations 
Cross-sectional studies estimate the prevalence of insomnia among patients attending primary care as 10-
50% (1). If we take the lower estimate of 10%, and assume conservatively that half of these patients receive 
an insomnia-related clinical code, then of our 8414 patients, we will find evidence of exposure to insomnia 
in at least 421 patients, while 7993 will be recorded as not exposed.  
According to the Sampsize power calculator (8), our study would be able to detect an odds ratio of 1.3 with 
80% power and 5% alpha risk, assuming a 5% rate of exposure among controls. Furthermore, our study will 
have a larger sample size than four of the five longitudinal studies judged suitable for inclusion in the 
aforementioned systematic review (3). It is therefore likely that our study will have adequate power to 
detect a clinically significant effect. 
J) Data Linkage Required: 
No data linkage is required for this study. 
K) and L) Study population and selection of controls 
A subsample of the data already acquired for the main study (Protocol  15_111R) will be used for the 
current study.  
Both cases and controls were originally drawn from the CPRD population. Dementia cases were defined on 
the basis of 1) a dementia code in their GP record in the period 2000-2012; and 2) an age of 65 years or 
older at the time of diagnosis. All patients in the CPRD who met this criteria were included (N = 47858). 
Controls were then drawn at random from the same CPRD population, and were matched on date of birth, 
sex and GP practice, with one control per case.  
For the current study, two new exclusion criteria will be applied: 
● Existing controls must not have been prescribed an antidementia drug (memantine, donepezil, 
galantamine, rivastigmine or tacrine) at any point in their record, up to two years after index date. 
This is to reduce the number of cases misclassified as controls. 
● Existing cases and controls must have at least 10 years of available data prior to the index date. 
Although it is a matched design, we will performed a standard, rather than a matched, analysis, following 
advice set out by Pearce (9), as this may lead to greater precision. The matching factors (age, gender and 
GP practice) will still be controlled for in the logistic regression.  
M) Exposures, Health Outcomes and Covariates 
The outcome of interest is dementia diagnosis, as defined by the code list in Appendix 2. 
The exposure of interest is insomnia, as measured by the number of months during the study period 
characterised by at least one insomnia consultation with the GP. An exposure window of 5-10 years prior to 
the index date has been chosen to reduce the possibility of a reverse causality bias. 
For RQ1, insomnia consultations will be identified by Read codes indicating insomnia, defined for this study 
as a difficulty initiating or maintaining sleep, leading to an insufficient amount of sleep and subjective 
complaints of non-restorative sleep (6,7,10). A tentative list of suitable Read codes is given in Appendix 1, 
but this will be added to and refined following consultation with clinical experts (GPs). We will not use Read 
codes indicating hypersomnia, disturbances of the sleep-wake cycle, sleep apnoea or abnormal behaviours 
during sleep.  
Table 1 lists possible confounding variables which may be controlled for in our analysis. The final list of 
adjustment variables will be refined after performing chi-squared tests of association with our outcome for 




GP practice  
Benzodiazepine and Z-drug use Possible confounder, as these drugs are often prescribed for 
insomnia, but may increase risk of dementia in people with 
insomnia (7). 
Our list of benzodiazepines and z-drugs will be derived from the 
BNF subsection ‘Hypnotics and Anxiolytics’ (we will look at older 
editions to ensure that we do not miss drugs no longer in useno 
longer in use). Following a method described by Gray et al (11), 
we will calculate a standardized daily dose (SDD) for each 
prescription by multiplying drug strength with the number of 
tablets dispensed, and then dividing the result by the minimum 
effective dose of that drug; we will then sum the SDD for all 
benzodiazepines and z-drugs prescribed during the exposure 
period to create the total standardized daily dose for that patient.  
Alcohol misuse Potential confounder, as implicated with both insomnia and 
dementia.  
 
Alcohol code list to be based on existing clinical codes for 
‘clinically significant alcohol misuse’ (12).  
History of mental illness (excluding 
SMI) 
Mental illness is a possible risk factor for dementia (13), and likely 
to confound the relationship between insomnia and dementia, as 
insomnia is more common in mental illness (14). 
Will use the existing anxiety, depression (mild and moderate 
codes only), eating disorder and personality disorders code lists 
from (15)  
History of severe mental illness (SMI, 
i.e. bipolar disorder, schizophrenia 
and severe depression) 
Considered separately from non-schizophrenia/bipolar mental 
disorders, due to differing treatment approaches. 
We will use the existing depression (severe codes only), 
schizophrenia spectrum and bipolar code lists from (15)  
Learning disability We will use existing learning disabilty codelist from (16) 
Chronic respiratory disease We will use existing ‘chronic pulmonary disease’ codelist from (17)  
Diabetes We will use existing diabetes code list from (18) 
Hypertension We will use existing hypertension code list from (18) 
Renal disease We will use existing CKD stages 3-5 codes lists from (18) 
CHD, vascular disease and heart 
failure 
We will use existing CHD, peripheral arterial disease and heart 
failure codelists from (18) 
Stroke We will use existing stroke code list from (18) 
Obstructive sleep apnoea Implicated as a risk factor for dementia (19), and may confound 
our results as may be incorrectly coded as ‘insomnia’.  
Code list to be drawn up following consultation with clinical 
experts. 
Smoking status Implicated as a risk factor for both dementia (20) and insomnia 
(21). 
Will use existing smoking codelist from (22) 
GP visit frequency Whether or not a patient sees their GP about insomnia may reflect 
their pattern of health use. By adjusting for GP visit frequency, we 
can reduce the potentially confounding effect of underlying 
problems such as health anxiety and physical comorbidity. 
Patients will be classified as ‘infrequent’, ‘moderate’ and 
‘frequent’ GP users, based on the frequency of their non-
insomnia-related GP consultations. 
Table 1:  List of potential confounding variables which may need to be controlled for logistic regression 
analysis. The exposure period for these variables will be the 5-10 years prior to the index date, unless 
otherwise stated. 
N) Data/ Statistical Analysis 
We will initially explore associations using cross-tabulations and chi-squared tests.  
We will use conditional logistical regression to estimate the odds ratio (OR) of developing dementia in 
those exposed compared to those not exposed, and to control for the aforementioned covariates. We will 
analyse the exposure in its continuous state rather than grouping the exposure into quantiles (e.g. ‘0-5 
months characterised by insomnia’). 
If insomnia and z-drug/benzodiazepine are found to be highly collinear, it may be necessary to repeat to 
repeat the analysis excluding all patients who have used these drugs, in order to understand whether 
insomnia is a risk factor for dementia independent of its association with z-drugs/benzodiazepines. 
For RQ3, a sensitivity analysis will be performed, repeating the analysis using different exposure windows: 
6-11 year prior to index date, and 7-12 years. The aim here is to ensure that any apparent association 
between insomnia and dementia is not the result of an arbitrary definition of the exposure period.  
O) Plan for addressing confounding 
Confounding will be partially addressed by the matched design, where cases and controls will be matched 
on sex, year of birth and general practice. Matching by practice will address differences in attitudes, 
recording, and provision of clinical care between GP practices. 
In addition, confounding will be addressed at the analysis stage through logistic regression.  
P) Plans for addressing missing data 
Given the nature of CPRD data, when a clinical entity is not recorded in a set time period, it is treated as 
“not present” rather than missing. If in a patient record there is no code for insomnia during the 5-10 years 
prior to dementia diagnosis, we would say that the patient did not have insomnia in that period, rather 
than that data on insomnia is missing. Only socio-demographic or lifestyle data may be considered missing 
if not recorded, e.g. BMI. If appropriate, we will use multiple imputation to address missingness in socio-
demographic or lifestyle factors.  
Q) Patient or user group involvement 
There is no patient or user group involvement. 
R) Plans for disseminating and communicating study results, including the presence or absence 
of any restrictions on the extent and timing of publication  
The study will result in the following outputs: 
1. Academic publications 
2. Presentations at health informatics and academic primary care conferences.  
3. Important clinical results may be disseminated to the public through Alzheimer’s Society talks and 
conferences and through Brighton Science Festival.  
We will give due consideration to preserving confidentiality in our dissemination and publications. We will 
adhere to CPRD policy that, when reporting the data, no cell should contain <5 events. 
S) Limitations of the study design, data sources, and analytic methods 
Our measure of insomnia does not give any indication of its severity (e.g. how many hours per night of 
sleep they are getting), and only a partial indication of its duration (a patient who sees their GP once about 
an episode of insomnia lasting several months would be considered in this study to have experienced  a 
single ‘insomnia month’). 
Furthermore, It is likely that the extent of insomnia will be underestimated, as a UK study found that only 
30% of those complaining of insomnia went on to have either a primary care consultation or prescription in 
the next 12 months about either mood or insomnia (23). Similarly, surveys in the US and Australia have 
found that respectively only 30% and 52% of those complaining of insomnia seek medical help for their 
complaint (24,25), while .  
In addition, GPs may record insomnia as free text (or not at all) rather than with a Read code, particularly 
where the consultation primarily focused on another problem.  
By requiring all patients to have at least 10 years of available records prior to the index date, we are 
introducing a bias, as this will favour patients who have stayed at the same GP practice for 10 years, 
indicating greater geographical stability. Patients who, for example, have to move to a care home in the 
years before dementia diagnosis, for example, would be excluded if this necessitates a change of GP 
practice.  
T) References 
1.  Falloon K, Arroll B, Elley CR, Fernando A 3rd. The assessment and management of insomnia in primary 
care. BMJ. 2011 May 27;342:d2899. 
2.  Spira AP, Chen-Edinboro LP, Wu MN, Yaffe K. Impact of sleep on the risk of cognitive decline and 
dementia. Curr Opin Psychiatry. 2014 Nov;27(6):478–83. 
3.  de Almondes KM, Costa MV, Malloy-Diniz LF, Diniz BS. Insomnia and risk of dementia in older adults: 
Systematic review and meta-analysis. J Psychiatr Res. 2016 Jun;77:109–15. 
4.  Hahn EA, Wang H-X, Andel R, Fratiglioni L. A Change in Sleep Pattern May Predict Alzheimer Disease. 
Am J Geriatr Psychiatry. 2014;22(11):1262–71. 
5.  Elwood PC, Bayer AJ, Fish M, Pickering J, Mitchell C, Gallacher JEJ. Sleep disturbance and daytime 
sleepiness predict vascular dementia. J Epidemiol Community Health. 2011 Sep;65(9):820–4. 
6.  Virta JJ, Heikkilä K, Perola M, Koskenvuo M, Räihä I, Rinne JO, et al. Midlife sleep characteristics 
associated with late life cognitive function. Sleep. 2013 Oct 1;36(10):1533–41, 1541A. 
7.  Chen P-L, Lee W-J, Sun W-Z, Oyang Y-J, Fuh J-L. Risk of Dementia in Patients with Insomnia and Long-
term Use of Hypnotics: A Population-based Retrospective Cohort Study. PLoS One. 2012;7(11):e49113. 
8.  Sampsize [Internet]. [cited 2017 Feb 28]. Available from: 
http://sampsize.sourceforge.net/iface/s3.html#ccp  
9.  Pearce N. Analysis of matched case-control studies. BMJ. 2016 Feb 25;352:i969. 
10.  Ahmed I, Thorpy M. Classification of sleep disorders. In: Sleep Disorders. 2008. p. 1–10. 
11.  Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, et al. Benzodiazepine use and risk of 
incident dementia or cognitive decline: prospective population based study. BMJ. 2016 Feb 2;352:i90. 
12.  Doyle M, While D, Mok PLH, Windfuhr K, Ashcroft DM, Kontopantelis E, et al. Suicide risk in primary 
care patients diagnosed with personality disorder: a nested case control study [Internet]. 
clinicalcodes.org. 2015 [cited 2017 Feb 14]. Available from: 
https://clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/32/ 
13.  Zilkens RR, Bruce DG, Duke J, Spilsbury K, Semmens JB. Severe psychiatric disorders in mid-life and risk 
of dementia in late- life (age 65-84 years): a population based case-control study. Curr Alzheimer Res. 
2014;11(7):681–93. 
14.  Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An 
opportunity for prevention? JAMA. 1989 Sep 15;262(11):1479–84. 
15.  Windfuhr K, While D, Kapur N, Ashcroft DM, Kontopantelis E, Carr MJ, et al. Website [Internet]. Suicide 
risk linked with clinical consultation frequency, psychiatric diagnoses and psychotropic medication 
prescribing in a national study of primary care patients. 2015 [cited 2017 Feb 14]. Available from: 
https://clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/38/ 
16.  Reilly S, Olier I, Planner C, Doran T, Reeves D, Ashcroft D, et al. Inequalities in physical co-morbidity: A 
longitudinal comparative observational study of people with severe mental illness in the UK [Internet]. 
ClinicalCodes.org. 2015 [cited 2017 Jan 27]. Available from: 
https://clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/26/ 
17.  Khan NF, Perera R, Harper S, Rose PW. Website [Internet]. Adaptation and validation of the Charlson 
Index for Read/OXMIS coded databases. 2010 [cited 2017 Feb 14]. Available from: 
https://clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/27/ 
18.  NHS Health and Social Care Information Centre. Website [Internet]. QOF Business Rules v24. 2012 
[cited 2017 Feb 14]. Available from: https://clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/1/ 
19.  Pan W, Kastin AJ. Can sleep apnea cause Alzheimer’s disease? Neurosci Biobehav Rev. 2014;47:656–
69. 
20.  Beydoun MA E al. Epidemiologic studies of modifiable factors associated with cognition and dementia: 
systematic review and meta-analysis. - PubMed - NCBI [Internet]. [cited 2017 Jan 27]. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/24962204 
21.  Lee JY E al. Trajectories of Cigarette Smoking Beginning in Adolescence Predict Insomnia in the Mid 
Thirties. - PubMed - NCBI [Internet]. [cited 2017 Jan 27]. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27008539 
22.  Carr MJ, Ashcroft DM, Kontopantelis E, While D, Awenat Y, Cooper J, et al. Short- and long-term risk of 
premature death in a nationally representative cohort of primary care patients with history of self-
harm [Internet]. ClinicalCodes.org. 2016 [cited 2017 Jan 25]. Available from: 
https://clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/41/ 
23.  Hayward R, Jordan KP, Croft P. Healthcare use in adults with insomnia: a longitudinal study. Br J Gen 
Pract. 2010 May;60(574):334–40. 
24.  Aikens JE, Rouse ME. Help-seeking for insomnia among adult patients in primary care. J Am Board Fam 
Pract. 2005 Jul;18(4):257–61. 
25.  Bartlett DJ, Marshall NS, Williams A, Grunstein RR. Predictors of primary medical care consultation for 
sleep disorders. Sleep Med. 2008 Dec;9(8):857–64. 
 
  
List of Appendices 
Appendix 1. Insomnia codes from CPRD data dictionary 
Appendix 2. Dementia codes from CPRD data dictionary 
 
  
Appendix 1: Codes relating to insomnia in CPRD data dictionary 
Read code Frequency of codes Read term 
R005200 587291 [D]Insomnia NOS 
1B1B.11 449676 C/O - insomnia 
R005.00 188663 [D]Sleep disturbances 
E274111 117094 Insomnia NOS 
Fy00.00 55901 Disorders of initiating and maintaining sleep 
1B1B.00 51359 Cannot sleep - insomnia 
663N.00 43757 Asthma disturbing sleep 
R005.11 7563 [D]Insomnia - symptom 
663N200 7459 Asthma disturbs sleep frequently 
663N100 6673 Asthma disturbs sleep weekly 
E274100 5018 Transient insomnia 
1B1B200 4208 Late insomnia 
1B1B000 3875 Initial insomnia 
Eu51000 2458 [X]Nonorganic insomnia 
1BX0.00 1450 Delayed onset of sleep 
E274200 1354 Persistent insomnia 
1B1B100 726 Middle insomnia 
E274D11 648 Restless sleep 
E274.12 169 Insomnia due to nonorganic sleep disorder 
E274E00 95 'Short-sleeper' 
1BX9.00 19 Light sleep 




Appendix 2: Codes relating to dementia in CPRD data dictionary 
Read code Read term 
Eu00..12 Senile/Presenile dementia 
E00..11 Senile dementia 
F110.00 Alzheimer's disease 
Eu024 Dementia in HIV disease 
Eu02z Unspecified dementia 
Eu01 Vascular dementia 
E000 Uncomplicated senile dementia  
F116 Lewy body disease 
Eu00 Dementia in Alzheimer's disease 
Eu00z11 [X]Alzheimer's dementia unspec 
Eu011 Multi-infarct dementia 
Eu012 Subcortical vascular dementia 
Eu023 Dementia in Parkinson's disease 
Eu01100 [X] Multi-infarct dementia 
Eu00112 [X]Senile dementia,Alzheimer's type 
E001 Presenile dementia 
F1100 Alzheimer's disease with early onset  
E0020 Senile dementia with paranoia 
Eu01z Vascular dementia unspecified 
E004 Arteriosclerotic dementia 
E0021 Senile dementia with depression 
E041.00 Dementia in conditions EC 
Eu00011 [X]Presenile dementia,Alzheimer's type 
Eu025 Lewy body dementia 
Eu10711 [X] Alcoholic dementia NOS 
Eu10711 Alcoholic dementia NOS 
E0013 Presenile dementia with depression 
Eu020 Dementia in Pick's disease 
Eu00z Dementia in Alzheimer's disease unspecified 
F112 Senile degeneration of the brain, not elsewhere classified  
E0012 Presenile dementia with paranoia 
Eu002 Dementia in Alzheimer's disease, atypical or mixed type 
Eu013 Mixed cortical and subcortical vascular dementia 
F1101 Alzheimer's disease with late onset 
Eu022 Dementia in Huntingdon's disease  
E003 Senile dementia with delirium 
E0014 Presenile dementia NOS 
Eu001 Dementia in Alzheimer's disease with late onset 
E002z Senile dementia with depressive or paranoid features NOS 
Eu004z Arteriosclerotic dementia NOS 
Eu0040 Uncomplicated arteriosclerotic dementia 
Eu0043 Arteriosclerotic dementia with depression 
Eu00113 [X]Primary degen dementia of Alzheimer's type, senile onset 
E002 Senile dementia with depressive or paranoid features 
E0010 Uncomplicated presenile dementia 
Eu01000 [X]Vascular dementia of acute onset 
Eu00111 [X]Alzheimer's disease type 1 
Eu02z11 [X] Presenile dementia NOS 
Eu000 Dementia in Alzheimer's disease with early onset 
E0011 Presenile dementia with delirium 
Eu041 Delirium superimposed on dementia 
Eu021 Dementia in Creutzfeldt-Jackob disease 
E012 Other alcoholic dementia 
Eu01y Other vascular dementia 
Eu0042 Arteriosclerotic dementia with paranoia 
Eu01111 [X]Predominantly cortical dementia 
Eu0041 Arteriosclerotic dementia with delirium 
Eu00012 [X]Primary degen dementia, Alzheimer's type, presenile onset 
Eu00013 [X]Alzheimer's disease type 2 
E02y100 Drug-induced dementia  
Eu02y00 [X] Dementia in other diseases classified elsewhere 
F111 Circumscribed brain atrophy including Pick's disease 
 
